Clinical trials: Depressive Symptoms
Depressive Disorder, Major
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.
- Trial name
- NCT03668600
- Testing
- Rapastinel
- Where
- 74 sites in United States
- Volunteers
- 230 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Depression
Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder
To evaluate the effectiveness of one algorithm for Major Depression Disorder (MDD) using medications available in the Brazilian Public Healthcare System (SUS), and assessment of the quality of life of these patients.
- Trial name
- NCT02901249
- Testing
- sertraline, Nortriptyline, Lithium
- Volunteers
- 68 people
- Sponsor
- Federal University of Rio Grande do Sul
Major Depressive Disorder
Ketamine in the Treatment of Depression
Depressed patients will be offered experimental treatment with a new, potentially fast-acting antidepressant called ketamine while being scanned by magnetic resonance imaging (MRI) to measure the chemical effect of the drug.
- Trial name
- NCT01558063
- Testing
- Ketamine, Saline, Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Columbia University
Major Depressive Disorder
AZD7268 Safety and Tolerability Study
The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.
- Trial name
- NCT01020799
- Testing
- AZD7268, Escitalopram
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- AstraZeneca
Depressive Symptoms, Depression
Evaluation of a Mobile Therapy for Elevated Depressive Symptoms
The purpose of this research study is to evaluate a mobile application (app) for depression treatment. Participants will be randomly assigned to either receive the mobile app, "Moodivate", or not.
- Trial name
- NCT04463914
- Testing
- Behavioral Activation Therapy app, Behavioral Activation Therapy app + EHR, Treatment as Usual
- Where
- United States
- Volunteers
- 649 people
- Sponsor
- Medical University of South Carolina
Depression, Melancholia
Antidepressant Treatment of Melancholia in Late Life
The purpose of this study is to compare the safety and effectiveness of a select serotonin re-uptake inhibitor (SSRI, sertraline) and a tricyclic antidepressant (TCA, nortriptyline) in outpatients over the age of 60 who have…
- Trial name
- NCT00000378
- Testing
- Sertraline, Nortriptyline
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
This a Phase 2a, multicenter, randomized, double-blind, placebo controlled 3 arm study to assess the safety and tolerability of multiple oral doses of REL-1017 25 mg and 50 mg as adjunctive therapy in the treatment of patients…
- Trial name
- NCT03051256
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Relmada Therapeutics, Inc.
Major Depression
Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
The purpose of this study is to find out what parts of the brain have increased or decreased activity when people are depressed and how antidepressant medicine changes this activity in depressed patients.
- Trial name
- NCT00532480
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Major Depressive Disorder
A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication
The objective of the present study is to evaluate whether vortioxetine (10 or 20 mg/day) is at least as effective as agomelatine (25 to 50 mg/day) in patients with depressive symptoms that showed inadequate response to Serotonin…
- Trial name
- REVIVE (NCT01488071)
- Testing
- Vortioxetine (Lu AA21004), Agomelatine
- Volunteers
- 495 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01153347
- Testing
- TC-5214
- Where
- 99 sites in United States, India and 1 more
- Volunteers
- 2,409 people
- Sponsor
- AstraZeneca
Depressive Disorder, Major
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
The purpose of the study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder…
- Trial name
- Aspire I (NCT03039192)
- Testing
- Esketamine, Standard of Care
- Where
- 56 sites in United States, Bulgaria and 9 more
- Volunteers
- 226 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD)
PET Imaging of mGLuR5 With Drug Challenge
This study is designed to look at that involvement of a process in the brain called the glutamate system in depression. Participants will undergo a screening session, up to two functional Magnetic Resonance Imaging (fMRI) scans…
- Trial name
- NCT01691092
- Testing
- Ketamine
- Where
- 3 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Yale University
Depression
Antidepressant Mechanisms of Transcranial Magnetic Stimulation
This study utilizes resting state fMRI, arterial spin labelling imaging, diffusion tensor imaging, structural MR-imaging, and MR-spectroscopy of GABA and Glutamate to probe the antidepressant mechanisms of repetitive transcranial…
- Trial name
- NCT02466230
- Testing
- Repetitive transcranial magnetic stimulation
- Volunteers
- 28 people
- Sponsor
- Weill Medical College of Cornell University
Depression, Depressive State
A Study to Compare the Pharmacokinetic Profiles of Etravil® Tablet 10mg and Etravil® Tablet 25mg
To evaluate the pharmacokinetics of single oral dose of Amitriptyline hydrochloride film-coated tablet 10mg \& 25mg
- Conditions
- Depression, Depressive State, Enuresis
- Trial name
- DWETR (NCT01367080)
- Testing
- DWETR10, DWETR25
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Major Depressive Disorder, Back Pain
Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults
The following primary hypotheses will be tested: 1. During Step 1: Major Depressive Disorder (MDD) or Chronic Low Back Pain (CLBP) in < 40% of the initial 60 subjects treated with duloxetine (DUL) + Clinical Management(CM) during…
- Conditions
- Major Depressive Disorder, Back Pain, Aged
- Trial name
- ACHIEVE2 (NCT00696293)
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Treatment Resistant Depression
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
This study is looking at the efficacy, durability, safety, and tolerability of multiple single doses of Ketamine vs. active placebo for treating patients with treatment resistant depression who are taking an antidepressant that…
- Trial name
- NCT01920555
- Testing
- Ketamine
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Massachusetts General Hospital
Depression, Dysthymia
Cognitive Behavioral Therapy (REBT/CBT) Evaluation for Dysthymia in the Practice of Clinical Social Work at Primary Care
Introduction: Minor psychiatric disorders are important in primary care, because of its high prevalence and consumption of healthcare resources generated.
- Conditions
- Depression, Dysthymia, Ambulatory Health Services
- Trial name
- NCT02112708
- Testing
- Rational-Emotive-Behavioral Therapy, Control Group usual care
- Where
- Spain
- Volunteers
- 129 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Major Depressive Disorder
Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy
The purpose of this study is to evaluate the intermediate-term efficacy and tolerability of a multiple-dosing ketamine infusion paradigm for the treatment of medication-refractory major depressive disorder (MDD).
- Trial name
- SAD-KIDS (NCT03889756)
- Testing
- Ketamine infusion, Midazolam infusion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Major Depressive Disorder
A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression
The purpose of this study is to evaluate the safety of PDC-1421 Capsule in healthy subject, find the effective adequate dose for the next stage of the study, and accumulate information of possible mechanism of its anti-depressive…
- Trial name
- NCT01774045
- Testing
- PDC-1421
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BioLite, Inc.
Depressive Disorder, Major
Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) or 225 mg of Rapastinel compared to placebo in the prevention of relapse in participants with major depressive disorder (MDD).
- Trial name
- NCT03614156
- Testing
- Rapastinel
- Where
- 52 sites in United States, Hungary and 3 more
- Volunteers
- 363 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc